JP2014058562A5 - - Google Patents

Download PDF

Info

Publication number
JP2014058562A5
JP2014058562A5 JP2013259956A JP2013259956A JP2014058562A5 JP 2014058562 A5 JP2014058562 A5 JP 2014058562A5 JP 2013259956 A JP2013259956 A JP 2013259956A JP 2013259956 A JP2013259956 A JP 2013259956A JP 2014058562 A5 JP2014058562 A5 JP 2014058562A5
Authority
JP
Japan
Prior art keywords
solution
composition
hydrophobic
chain
protective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013259956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014058562A (ja
JP5878912B2 (ja
Filing date
Publication date
Priority claimed from US11/971,482 external-priority patent/US20090176892A1/en
Application filed filed Critical
Publication of JP2014058562A publication Critical patent/JP2014058562A/ja
Publication of JP2014058562A5 publication Critical patent/JP2014058562A5/ja
Application granted granted Critical
Publication of JP5878912B2 publication Critical patent/JP5878912B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013259956A 2008-01-09 2013-12-17 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法 Active JP5878912B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/971,482 2008-01-09
US11/971,482 US20090176892A1 (en) 2008-01-09 2008-01-09 Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010542394A Division JP2011509311A (ja) 2008-01-09 2009-01-09 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014110975A Division JP2014156486A (ja) 2008-01-09 2014-05-29 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Publications (3)

Publication Number Publication Date
JP2014058562A JP2014058562A (ja) 2014-04-03
JP2014058562A5 true JP2014058562A5 (enExample) 2014-07-17
JP5878912B2 JP5878912B2 (ja) 2016-03-08

Family

ID=40845092

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010542394A Withdrawn JP2011509311A (ja) 2008-01-09 2009-01-09 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2013259956A Active JP5878912B2 (ja) 2008-01-09 2013-12-17 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2014110975A Withdrawn JP2014156486A (ja) 2008-01-09 2014-05-29 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2016104890A Active JP6244400B2 (ja) 2008-01-09 2016-05-26 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2017149174A Active JP6342556B2 (ja) 2008-01-09 2017-08-01 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010542394A Withdrawn JP2011509311A (ja) 2008-01-09 2009-01-09 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014110975A Withdrawn JP2014156486A (ja) 2008-01-09 2014-05-29 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2016104890A Active JP6244400B2 (ja) 2008-01-09 2016-05-26 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2017149174A Active JP6342556B2 (ja) 2008-01-09 2017-08-01 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Country Status (4)

Country Link
US (3) US20090176892A1 (enExample)
EP (1) EP2240165B1 (enExample)
JP (5) JP2011509311A (enExample)
WO (1) WO2009089506A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520040A (ja) 2005-12-19 2009-05-21 ファーマイン コーポレーション 治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
JP5281358B2 (ja) * 2008-10-27 2013-09-04 学校法人常翔学園 高分子、経上皮吸収促進剤、及び医薬用製剤
AU2010292329B2 (en) * 2009-09-09 2016-07-21 Pharmain Corporation Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same
WO2012051458A1 (en) * 2010-10-14 2012-04-19 Nitto Denko Corporation Nucleic acid delivery compounds
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CA2966333C (en) * 2014-11-03 2023-02-14 Pharmain Corporation Method of production of graft co-polymer excipient with a superior peptide and protein binding property
WO2018017954A1 (en) * 2016-07-21 2018-01-25 Rutgers, The State University Of New Jersey Antimicrobial cationic systems and methods of use
EP3740227A1 (fr) 2017-12-07 2020-11-25 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3083086A1 (fr) * 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
WO2019115411A1 (fr) * 2017-12-07 2019-06-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
MX2020005916A (es) 2017-12-07 2020-10-19 Adocia Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
WO2019110797A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US7138486B2 (en) * 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5527524A (en) * 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
US5116603A (en) 1989-01-31 1992-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Oral antifungal preventative, and method of use
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5837747A (en) * 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
US5770563A (en) * 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
JP4074658B2 (ja) * 1992-04-03 2008-04-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自己構築ポリヌクレオチド送達システム
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
DE69332952T2 (de) * 1992-09-04 2004-02-19 The General Hospital Corp., Boston Diagnostische und therapeutische Einheiten enthaltende biokompatible Polymere
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5763585A (en) * 1993-10-13 1998-06-09 Anergen, Inc. Method of making MHC-peptide complexes using metal chelate affinity chromatography
CA2161684C (en) * 1994-03-07 2010-11-09 Larry R. Wilson Bioactive and/or targeted dendrimer conjugates
US5466467A (en) * 1994-03-30 1995-11-14 The United States Of America As Represented By The Secretary Of The Navy Liposomes containing polymerized lipids for non-covalent immobilization of proteins and enzymes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20010006943A1 (en) * 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US5855610A (en) * 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
JPH11507697A (ja) * 1995-06-09 1999-07-06 エヌ． ドロハン，ウィリアム キチンヒドロゲル、それらの製造方法及び利用
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
WO1997014740A1 (en) * 1995-10-19 1997-04-24 Receptagen Corporation Discrete-length polyethylene glycols
CZ297979B6 (cs) 1996-03-12 2007-05-16 Pg-Txl Company, L. P. Kompozice obsahující protinádorové lécivo konjugované s ve vode rozpustným polymerem, její pouzití pro výrobu léciva a implantovatelná lékarská pomucka
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6153211A (en) * 1997-07-18 2000-11-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances
US6468532B1 (en) * 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB9811059D0 (en) * 1998-05-23 1998-07-22 Univ Strathclyde Polyamino acid vesicles
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
EP2028269B1 (en) * 1998-08-10 2015-10-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or Exendin-4 and uses thereof
DE69935435T2 (de) * 1998-08-12 2007-12-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Mittels Ammoniumsulfatgradient hergestellte liposomale analgetische Zusammensetzungen
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
BR0008590A (pt) * 1999-01-08 2001-10-30 Emisphere Tech Inc Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
US6365173B1 (en) * 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
IL138990A0 (en) * 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US6926304B2 (en) * 2000-02-22 2005-08-09 Daicel Chemical Industries, Ltd. Airbag generator, deflector member, coolant/filter means support member, coolant, and housing
MXPA02009031A (es) * 2000-03-14 2004-08-19 Amylin Pharmaceuticals Inc Efectos del peptido-1(7-36) tipo glucagon en la motilidad antro-piloro.duodenal.
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
CN1462191B (zh) * 2000-05-19 2013-07-24 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
AU8466501A (en) * 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
US20040092432A1 (en) * 2000-08-24 2004-05-13 Thomas Jefferson University Peptide compositions with effects on cerebral health
US6521736B2 (en) * 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
AU775663B2 (en) * 2000-10-20 2004-08-12 Amylin Pharmaceuticals, Inc. Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
US7259233B2 (en) * 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002228608A1 (en) * 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
JP4775985B2 (ja) * 2000-12-27 2011-09-21 三井化学株式会社 重合体及びその製造方法
ES2315350T3 (es) * 2001-01-12 2009-04-01 Waratah Pharmaceuticals Inc. Composiciones para la introduccion de la neogenesis de islotes, que contienen unos ligandos para el receptor de gastrina/cck y ligandos para el receptor de efg.
JP2005506956A (ja) * 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
JP5562510B2 (ja) * 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
US6586524B2 (en) * 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
IL160493A0 (en) * 2001-08-23 2004-07-25 Lilly Co Eli Glucagon-like peptide-1 analogs
PL373846A1 (en) * 2001-10-01 2005-09-19 Eli Lilly And Company Method of reducing mortality and morbidity associated with critical illnesses
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
AU2002349513B2 (en) * 2001-11-26 2007-10-18 Asubio Pharma Co., Ltd. Medicinal compositions for nasal absorption
JP4417113B2 (ja) * 2002-02-20 2010-02-17 エミスフェアー・テクノロジーズ・インク Ｇｌｐ−１分子の投与方法
ATE494010T1 (de) * 2002-02-27 2011-01-15 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US6705987B2 (en) * 2002-04-17 2004-03-16 Endocare, Inc. Penile seal and constriction ring
MXPA04012497A (es) * 2002-07-04 2005-07-14 Zealand Pharma As Glp-1 y metodos para tratar la diabetes.
WO2004014451A1 (en) 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery systems, medical devices, and methods
AU2003273300A1 (en) 2002-09-06 2004-03-29 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
GB0221941D0 (en) * 2002-09-20 2002-10-30 Univ Strathclyde Polysoaps
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
EP1610765B1 (en) * 2003-03-31 2008-08-13 ALZA Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
WO2005000222A2 (en) * 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
EP2292253A3 (en) * 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CN102940879B (zh) * 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
US20060247167A1 (en) * 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
WO2005058252A2 (en) * 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
JP2007527431A (ja) * 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
FR2867679B1 (fr) * 2004-03-17 2008-08-22 Oreal Composition cosmetiques comprenant des polyamines modifiees et utilisations desdites compositions.
US7985424B2 (en) * 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
EP1737899B1 (en) * 2004-04-20 2015-07-08 Dendritic Nanotechnologies, Inc. Dendritic polymers with enhanced amplification and interior functionality
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20060134166A1 (en) * 2004-05-25 2006-06-22 Luthra Ajay K Absorbable biocompatible materials
JP2008512350A (ja) * 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
WO2006014425A1 (en) * 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
PT1773878E (pt) * 2004-07-19 2015-06-05 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
KR100675834B1 (ko) * 2004-10-28 2007-01-29 한국전자통신연구원 루프백 형 파장분할다중방식의 수동형 광 네트워크
US20060233857A1 (en) * 2005-04-14 2006-10-19 Amsden Brian G Degradable elastomeric network
WO2007024899A2 (en) 2005-08-23 2007-03-01 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
WO2007030706A1 (en) 2005-09-08 2007-03-15 New England Medical Center Hospitals, Inc. Fragments of the glucagon-like peptide-i and uses thereof
EP1931397B1 (en) * 2005-10-05 2009-04-08 SCA Hygiene Products AB Absorbent article comprising hydrophilic and hydrophobic regions
ES2625109T3 (es) 2005-10-25 2017-07-18 Starpharma Pty Limited Compuestos macromoleculares que tienen estequiometría controlada
HRP20160866T1 (hr) 2005-11-04 2016-10-07 Glaxosmithkline Llc Postupci primjene hipoglikemijskih sredstava
JP2009520040A (ja) 2005-12-19 2009-05-21 ファーマイン コーポレーション 治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
CN104524596B (zh) 2006-01-20 2018-10-09 星药股份有限公司 经修饰的大分子
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same

Similar Documents

Publication Publication Date Title
JP2014058562A5 (enExample)
JP2011509311A5 (enExample)
Ding et al. Weak bond-based injectable and stimuli responsive hydrogels for biomedical applications
Ryu et al. Chitosan oral patches inspired by mussel adhesion
Li et al. Biodegradable and injectable hydrogels in biomedical applications
Kumar et al. Why Chitosan? From properties to perspective of mucosal drug delivery
Chen et al. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules
Hutanu et al. Recent applications of polyethylene glycols (PEGs) and PEG derivatives
US9265723B2 (en) Long acting insulin composition
Werle et al. Modified chitosans for oral drug delivery
Prabaharan Chitosan derivatives as promising materials for controlled drug delivery
Sajeesh et al. Novel pH responsive polymethacrylic acid–chitosan–polyethylene glycol nanoparticles for oral peptide delivery
ES2733734T3 (es) Profármacos que comprenden un conjugado exendina enlazador
Sonker et al. Review of recent advances and their improvement in the effectiveness of hydrogel-based targeted drug delivery: A hope for treating cancer
Wang et al. Development of zwitterionic polymer-based doxorubicin conjugates: tuning the surface charge to prolong the circulation and reduce toxicity
ES2679195T3 (es) Método para la preparación de un sistema de liberación controlada
JP2023504853A (ja) 炎症応答性を有する抗炎症性ハイドロゲル
Schulz et al. Improving oral drug bioavailability with polycations?
JP2014514275A5 (enExample)
JP2012532185A5 (enExample)
KR101363498B1 (ko) 생리활성 폴리펩티드 또는 단백질 내포 고분자 폴리머 미셀및 그 제조방법
JP2013536198A (ja) 治療用ペプチド−ポリマーの複合体、粒子、組成物および関連の方法
Cui et al. Preparation and evaluation of chitosan‐ethylenediaminetetraacetic acid hydrogel films for the mucoadhesive transbuccal delivery of insulin
Berezin et al. Chitosan conjugates with biologically active compounds: Design strategies, properties, and targeted drug delivery
Lee et al. Targeted cellular delivery of robust enzyme nanoparticles for the treatment of drug-induced hepatotoxicity and liver injury